Evidence map›Paper›PMID 26854157›Full record

ReviewDiagnostics (Basel, Switzerland)2015

PET/MRI in Oncological Imaging: State of the Art.

Usman Bashir, Andrew Mallia, James Stirling, John Joemon, Jane MacKewn, Geoff Charles-Edwards, Vicky Goh, Gary J Cook

Open access · goldAbstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Integrated [European journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. PET/CT and PET/MRI in ophthalmic oncology (Review).International journal of oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Usman BashirCancer Imaging Department, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, SE1 7EH, UK. usman.bashir@kcl.ac.uk.
Andrew MalliaCancer Imaging Department, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, SE1 7EH, UK. andrew.mallia@kcl.ac.uk.
James StirlingCancer Imaging Department, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, SE1 7EH, UK. james.stirling@nhs.net.
John JoemonPET Imaging Centre and the Division of Imaging Sciences and Biomedical Engineering, King's College London, London, SE1 7EH, UK. joemon.john@gstt.nhs.uk.
Jane MacKewnPET Imaging Centre and the Division of Imaging Sciences and Biomedical Engineering, King's College London, London, SE1 7EH, UK. jane.mackewn@kcl.ac.uk.
Geoff Charles-EdwardsCancer Imaging Department, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, SE1 7EH, UK. geoff.charles-edwards@kcl.ac.uk.
Vicky GohCancer Imaging Department, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, SE1 7EH, UK. vicky.goh@kcl.ac.uk.
Gary J CookCancer Imaging Department, Division of Imaging Sciences and Biomedical Engineering, King's College London, London, SE1 7EH, UK. gary.cook@kcl.ac.uk.
King's College London · GBGuy's and St Thomas' NHS Foundation Trust · GB

Funding

Cancer Research UK 16463Cancer Research UK 20000
6 · The paper itself

Abstract

Positron emission tomography (PET) combined with magnetic resonance imaging (MRI) is a hybrid technology which has recently gained interest as a potential cancer imaging tool. Compared with CT, MRI is advantageous due to its lack of ionizing radiation, superior soft-tissue contrast resolution, and wider range of acquisition sequences. Several studies have shown PET/MRI to be equivalent to PET/CT in most oncological applications, possibly superior in certain body parts, e.g., head and neck, pelvis, and in certain situations, e.g., cancer recurrence. This review will update the readers on recent advances in PET/MRI technology and review key literature, while highlighting the strengths and weaknesses of PET/MRI in cancer imaging.

Indexed as

cancerdiagnosisimagingMR-PETPET/MRI

Identifiers

PMID26854157
PMCPMC4665605
OpenAlexW2097287643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.